ACS Pharmacology and Translational Science最新文献_第8页

Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies 间充质干细胞衰老机制的新动向及其对治疗策略的影响

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-17 DOI: 10.1021/acsptsci.4c0028410.1021/acsptsci.4c00284

Jing Wang*, Muqing Zhang and Hu Wang*,

{"title":"Emerging Landscape of Mesenchymal Stem Cell Senescence Mechanisms and Implications on Therapeutic Strategies","authors":"Jing Wang*, Muqing Zhang and Hu Wang*, ","doi":"10.1021/acsptsci.4c0028410.1021/acsptsci.4c00284","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00284https://doi.org/10.1021/acsptsci.4c00284","url":null,"abstract":"Mesenchymal stem cells (MSCs) hold significant promise for regenerative medicine and tissue engineering due to their unique multipotent differentiation ability and immunomodulatory properties. MSC therapy is widely discussed and utilized in clinical treatment. However, during both in vitro expansion and in vivo transplantation, MSCs are prone to senescence, an irreversible growth arrest characterized by morphological, gene expression, and functional changes in genomic regulation. The microenvironment surrounding MSCs plays a crucial role in modulating their senescence phenotype, influenced by factors such as hypoxia, inflammation, and aging status. Numerous strategies targeting MSC senescence have been developed, including senolytics and senomorphic agents, antioxidant and exosome therapies, mitochondrial transfer, and niche modulation. Novel approaches addressing replicative senescence have also emerged. This paper comprehensively reviews the current molecular manifestations of MSC senescence, addresses the environmental impact on senescence, and highlights potential therapeutic strategies to mitigate senescence in MSC-based therapies. These insights aim to enhance the efficacy and understanding of MSC therapies.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2306–2325 2306–2325"},"PeriodicalIF":4.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141957450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration 芳香胺 N-乙酰转移酶 1 的小分子抑制剂可减轻细胞呼吸作用

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-17 DOI: 10.1021/acsptsci.4c0028210.1021/acsptsci.4c00282

Chandra Choudhury, James E. Egleton, Neville J. Butcher, Angela J. Russell and Rodney F. Minchin*,

{"title":"Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration","authors":"Chandra Choudhury, James E. Egleton, Neville J. Butcher, Angela J. Russell and Rodney F. Minchin*, ","doi":"10.1021/acsptsci.4c0028210.1021/acsptsci.4c00282","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00282https://doi.org/10.1021/acsptsci.4c00282","url":null,"abstract":"Arylamine N-acetyltransferase 1 (NAT1) expression has been shown to attenuate mitochondrial function, suggesting it is a promising drug target in diseases of mitochondrial dysfunction. Here, several second-generation naphthoquinones have been investigated as small molecule inhibitors of NAT1. The results show that the compounds inhibit both in vitro and in whole cells. A lead compound (Cmp350) was further investigated for its ability to alter mitochondrial metabolism in MDA-MB-231 cells. At concentrations that inhibited NAT1 by over 85%, no overt toxicity was observed. Moreover, the inhibitor decreased basal respiration and reserve respiratory capacity without affecting ATP production. Cells treated with Cmp350 were almost exclusively dependent on glucose as a fuel source. We postulate that Cmp350 is an excellent lead compound for the development of NAT1-targeted inhibitors as both experimental tools and therapeutics in the treatment of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2326–2332 2326–2332"},"PeriodicalIF":4.9,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141955492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis 从三维模型、探针模拟和突变中探索 CC-Chemokine Receptor 4 的细胞内异构位点

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-16 DOI: 10.1021/acsptsci.4c0033010.1021/acsptsci.4c00330

Tianyi Ding, Abdul-Akim Guseinov, Graeme Milligan, Bianca Plouffe* and Irina G. Tikhonova*,

{"title":"Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis","authors":"Tianyi Ding, Abdul-Akim Guseinov, Graeme Milligan, Bianca Plouffe* and Irina G. Tikhonova*, ","doi":"10.1021/acsptsci.4c0033010.1021/acsptsci.4c00330","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00330https://doi.org/10.1021/acsptsci.4c00330","url":null,"abstract":"We applied our previously developed probe confined dynamic mapping protocol, which combines enhanced sampling molecular dynamics (MD) simulations and fragment-based approaches, to identify the binding site of GSK2239633A (N-[[3-[[3-[(5-chlorothiophen-2-yl)sulfonylamino]-4-methoxyindazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methylpropanamide), a selective CC-chemokine receptor type 4 (CCR4) negative allosteric modulator, using CCR4 homology and AlphaFold models. By comparing the performance across five computational models, we identified conserved (K3108.49 and Y3047.53) and non-conserved (M2436.36) residue hotspots for GSK2239633A binding, which were validated by mutagenesis and bioluminescence resonance energy transfer assay. Further analysis of 3D models and MD simulations highlighted the pair of residues 6.36 and 7.56 that might account for antagonist selectivity among chemokine receptors. Our in silico protocol provides a promising approach for characterizing ligand binding sites in membrane proteins, considering receptor dynamics and adaptability and guiding protein template selection for ligand design.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2516–2526 2516–2526"},"PeriodicalIF":4.9,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00330","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141957188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A First Insight into the Developability of an Immunoglobulin G3: A Combined Computational and Experimental Approach 首次洞察免疫球蛋白 G3 的可开发性：计算与实验相结合的方法

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-15 DOI: 10.1021/acsptsci.4c0027110.1021/acsptsci.4c00271

Georgina B. Armstrong*, Alan Lewis, Vidhi Shah, Paul Taylor, Craig J. Jamieson, Glenn A. Burley, William Lewis and Zahra Rattray*,

{"title":"A First Insight into the Developability of an Immunoglobulin G3: A Combined Computational and Experimental Approach","authors":"Georgina B. Armstrong*, Alan Lewis, Vidhi Shah, Paul Taylor, Craig J. Jamieson, Glenn A. Burley, William Lewis and Zahra Rattray*, ","doi":"10.1021/acsptsci.4c0027110.1021/acsptsci.4c00271","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00271https://doi.org/10.1021/acsptsci.4c00271","url":null,"abstract":"Immunoglobulin G 3 (IgG3) monoclonal antibodies (mAbs) are high-value scaffolds for developing novel therapies. Despite their wide-ranging therapeutic potential, IgG3 physicochemical properties and developability characteristics remain largely under-characterized. Protein–protein interactions elevate solution viscosity in high-concentration formulations, impacting physicochemical stability, manufacturability, and the injectability of mAbs. Therefore, in this manuscript, the key molecular descriptors and biophysical properties of a model anti-IL-8 IgG1 and its IgG3 ortholog are characterized. A computational and experimental framework was applied to measure molecular descriptors impacting their downstream developability. Findings from this approach underpin a detailed understanding of the molecular characteristics of IgG3 mAbs as potential therapeutic entities. This work is the first report examining the manufacturability of IgG3 for high-concentration mAb formulations. While poorer conformational and colloidal stability and elevated solution viscosity were observed for IgG3, future efforts controlling surface potential through sequence-engineering of solvent-accessible patches can be used to improve biophysical parameters that dictate mAb developability.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2439–2451 2439–2451"},"PeriodicalIF":4.9,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00271","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141957119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease 心肌肌钙蛋白 I 快速检测试剂盒：基于酶联免疫底物分析的可靠生物传感器，用于心血管疾病中心肌梗死的日用裸眼检测和药代动力学研究

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-15 DOI: 10.1021/acsptsci.4c0021810.1021/acsptsci.4c00218

Yu-Fang Hsieh*, and , Kuan-Jiuh Lin*,

{"title":"Rapid-Test Kit for Cardiac Troponin I: A Reliable Enzyme-Linked-Immuno-Substrate-Assay-Based Biosensor for Daily-Use Naked-Eye Detection and Pharmacokinetic Studies for Myocardial Infarction in Cardiovascular Disease","authors":"Yu-Fang Hsieh*,  and , Kuan-Jiuh Lin*, ","doi":"10.1021/acsptsci.4c0021810.1021/acsptsci.4c00218","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00218https://doi.org/10.1021/acsptsci.4c00218","url":null,"abstract":"Myocardial infarction (MI) is a severe cardiovascular event that can lead to death. Cardiac troponin I (cTnI) is an MI biomarker in the circulation system; however, methods for detecting cTnI protein require substantial time, tedious operations, an expensive reader for translating signals, and a lot of reagents. This study aims to create a cTnI protein test kit with results easily distinguished by color differences, explicitly focusing on the resolution between different concentrations that eyes can discern. These results will aid in creating a commercial, portable, convenient, daily-use rapid-test kit. This study proposes a cTnI biosensor that the naked eye can perceive, performs diagnoses based on pattern color, does not require a reader machine, is easy to operate, and is portable. Our device shortens diagnosis time, has a 0.32–200 ng/mL quantitative analysis range in the human serum matrix, achieves a 0.32 ng/mL limit of detection, and exhibits many advantages compared to a traditional cTnI ELISA plate.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2369–2378 2369–2378"},"PeriodicalIF":4.9,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141956940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials 基于生理学的纳米材料药物代谢动力学 (PBPK) 建模进展

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-11 DOI: 10.1021/acsptsci.4c0025010.1021/acsptsci.4c00250

Ozlem Ozbek, Destina Ekingen Genc and Kutlu O. Ulgen*,

{"title":"Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials","authors":"Ozlem Ozbek, Destina Ekingen Genc and Kutlu O. Ulgen*, ","doi":"10.1021/acsptsci.4c0025010.1021/acsptsci.4c00250","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00250https://doi.org/10.1021/acsptsci.4c00250","url":null,"abstract":"Nanoparticles (NPs) have been widely used to improve the pharmacokinetic properties and tissue distribution of small molecules such as targeting to a specific tissue of interest, enhancing their systemic circulation, and enlarging their therapeutic properties. NPs have unique and complicated in vivo disposition properties compared to small molecule drugs due to their complex multifunctionality. Physiologically based pharmacokinetic (PBPK) modeling has been a powerful tool in the simulation of the absorption, distribution, metabolism, and elimination (ADME) characteristics of the materials, and it can be used in the characterization and prediction of the systemic disposition, toxicity, efficacy, and target exposure of various types of nanoparticles. In this review, recent advances in PBPK model applications related to the nanoparticles with unique properties, and dispositional features in the biological systems, ADME characteristics, the description of transport processes of nanoparticles in the PBPK model, and the challenges in PBPK model development of nanoparticles are delineated and juxtaposed with those encountered in small molecule models. Nanoparticle related, non-nanoparticle-related, and interspecies-scaling methods applied in PBPK modeling are reviewed. In vitro to in vivo extrapolation (IVIVE) methods being a promising computational tool to provide in vivo predictions from the results of in vitro and in silico studies are discussed. Finally, as a recent advancement ML/AI-based approaches and challenges in PBPK modeling in the estimation of ADME parameters and pharmacokinetic (PK) analysis results are introduced.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2251–2279 2251–2279"},"PeriodicalIF":4.9,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141955368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2 基于 11C 标记的异吲哚酮正异位调节剂的放射合成与评估，用于对代谢谷氨酸受体 2 进行正电子发射断层扫描成像

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-10 DOI: 10.1021/acsptsci.4c0026110.1021/acsptsci.4c00261

Yinlong Li, Kenneth Dahl, Peter Johnström, Katarina Varnäs, Lars Farde, Christer Halldin, Amy Medd, Donna Maier, Mark E. Powell, Jiahui Chen, Richard Van, Jimmy Patel, Ahmad Chaudhary, Yabiao Gao, Zhendong Song, Ahmed Haider, Yihan Shao, Charles S. Elmore, Steven Liang* and Magnus Schou*,

{"title":"Radiosynthesis and Evaluation of 11C-Labeled Isoindolone-Based Positive Allosteric Modulators for Positron Emission Tomography Imaging of Metabotropic Glutamate Receptor 2","authors":"Yinlong Li, Kenneth Dahl, Peter Johnström, Katarina Varnäs, Lars Farde, Christer Halldin, Amy Medd, Donna Maier, Mark E. Powell, Jiahui Chen, Richard Van, Jimmy Patel, Ahmad Chaudhary, Yabiao Gao, Zhendong Song, Ahmed Haider, Yihan Shao, Charles S. Elmore, Steven Liang* and Magnus Schou*, ","doi":"10.1021/acsptsci.4c0026110.1021/acsptsci.4c00261","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00261https://doi.org/10.1021/acsptsci.4c00261","url":null,"abstract":"The metabotropic glutamate receptor 2 (mGluR2) has emerged as a potential therapeutic target for the treatment of various neurological diseases, prompting substantial interest in the development of mGluR2-targeted drug candidates. As part of our medicinal chemistry program, we synthesized a series of isoindolone derivatives and assessed their potential as mGluR2 positive allosteric modulators (PAMs). Notably, AZ12559322 exhibited high affinity (Ki mGluR2 = 1.31 nM) and an excellent in vitro binding specificity of 89% while demonstrating selectivity over other mGluR subtypes (>4000-fold). Autoradiography with the radiolabeled counterpart, [3H]AZ12559322, revealed a heterogeneous accumulation with the highest binding in mGluR2-rich brain regions. Radioligand binding was significantly reduced by pretreatment with nonradioactive mGluR2 PAMs in brains of rats and nonhuman primates. Although positron emission tomography imaging of [11C]AZ12559322 (6a) revealed low brain uptake in a nonhuman primate, this study provides valuable guidance to further design novel isoindolone-based mGluR2 PAMs with improved brain exposure.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2414–2423 2414–2423"},"PeriodicalIF":4.9,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00261","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141954731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mass Spectrometry Imaging Reveals Region-Specific Lipid Alterations in the Mouse Brain in Response to Efavirenz Treatment 质谱成像揭示小鼠脑内特定区域脂质变化对依非韦伦治疗的反应

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-09 DOI: 10.1021/acsptsci.4c0022810.1021/acsptsci.4c00228

Nav Raj Phulara, Apurv Rege, Charles J. Bieberich and Herana Kamal Seneviratne*,

{"title":"Mass Spectrometry Imaging Reveals Region-Specific Lipid Alterations in the Mouse Brain in Response to Efavirenz Treatment","authors":"Nav Raj Phulara, Apurv Rege, Charles J. Bieberich and Herana Kamal Seneviratne*, ","doi":"10.1021/acsptsci.4c0022810.1021/acsptsci.4c00228","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00228https://doi.org/10.1021/acsptsci.4c00228","url":null,"abstract":"Efavirenz (EFV) is a commonly used drug to treat human immunodeficiency virus infection and is known to exert adverse effects on the brain. Although it is known that EFV is associated with abnormal plasma lipid levels, the changes in the spatial localization of individual lipid molecules in brain tissue following EFV treatment are yet to be explored. In this study, we employed a matrix-assisted laser desorption/ionization mass spectrometry imaging approach to determine region-specific lipid alterations in mouse brains following EFV treatment. We detected unique spatial localization patterns of phosphatidylcholine (PC), sphingomyelin (SM), ceramide phosphoinositol (PI-Cer), and hexosylceramide (HexCer) molecules in the mouse brain. Interestingly, PC(32:0), PC(38:5), and SM(36:1;O2) showed high abundance in the hippocampus region, whereas PI-Cer(38:8) exhibited low abundance in the hippocampus region of the EFV-treated mouse brains. Additionally, we observed low abundance of PC(38:6), PC(40:6), and PI-Cer(40:3) in the thalamus region of the EFV-treated mouse brains. Furthermore, SM(40:1;O2), SM(42:2;O2), SM(42:1;O2), SM(43:2;O2), and SM(43:1;O2) exhibited their accumulation in the corpus callosum region of the EFV-treated mouse brains as compared to controls. However, HexCer(42:1;O3) exhibited depletion in the corpus callosum region in response to EFV treatment. To characterize the expression patterns of proteins, including lipid metabolizing enzymes, in response to EFV treatment, mass spectrometry-based proteomics was utilized. From these, the expression levels of 12 brain proteins were found to be significantly decreased following EFV treatment. Taken together, these multiomics data provide important insights into the effects of EFV on brain lipid metabolism.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2379–2390 2379–2390"},"PeriodicalIF":4.9,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141956992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Linker Entities on Pharmacokinetics of 111In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin Binder 连接体实体对带有白蛋白粘合剂的 111In 标记前列腺特异性膜抗原靶向配体药代动力学的影响

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-08 DOI: 10.1021/acsptsci.4c0025710.1021/acsptsci.4c00257

Nobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe and Masahiro Ono*,

{"title":"Effect of Linker Entities on Pharmacokinetics of 111In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin Binder","authors":"Nobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe and Masahiro Ono*, ","doi":"10.1021/acsptsci.4c0025710.1021/acsptsci.4c00257","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00257https://doi.org/10.1021/acsptsci.4c00257","url":null,"abstract":"In the field of radiopharmaceutical development targeting cancer, an albumin binder (ALB) is commonly used to improve accumulation of radioligands in tumors because it has high binding affinity for albumin and extends the circulation time of radioligands. The further development of ALB-containing radioligands is also expected to regulate their pharmacokinetics. In this study, we newly designed and synthesized [111In]In-PNT-DA1 derivatives, prostate-specific membrane antigen (PSMA)-targeting radioligands including a functional linker (d-glutamic acid or 4-(aminomethyl)benzoic acid), and evaluated the relationships among the structure, albumin-binding affinity, and pharmacokinetics. These derivatives showed a different binding affinity for albumin by the introduction of a linker. Biodistribution studies revealed that the introduction of a linker affects the pharmacokinetics of each derivative. The biodistribution studies also suggested that moderate albumin-binding affinity enhances the tumor/kidney ratio of the derivative. SPECT imaging using [111In]In-PNT-DA3 with the highest tumor/kidney ratio among [111In]In-PNT-DA1 derivatives led to clear visualization of a PSMA-positive LNCaP tumor. The results suggest that the appropriate introduction of linker entities may be necessary to improve the pharmacokinetics of PSMA-targeting radioligands.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2401–2413 2401–2413"},"PeriodicalIF":4.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141956825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies 一种用于体内研究的高效力、口服生物可用吡唑衍生大麻素 CB2 受体选择性全激动剂

IF 4.9

ACS Pharmacology and Translational Science Pub Date : 2024-07-08 DOI: 10.1021/acsptsci.4c0026910.1021/acsptsci.4c00269

Andrea Chicca, Daniel Bátora, Christoph Ullmer, Antonello Caruso, Sabine Grüner, Jürgen Fingerle, Thomas Hartung, Roland Degen, Matthias Müller, Uwe Grether, Pal Pacher* and Jürg Gertsch*,

{"title":"A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies","authors":"Andrea Chicca, Daniel Bátora, Christoph Ullmer, Antonello Caruso, Sabine Grüner, Jürgen Fingerle, Thomas Hartung, Roland Degen, Matthias Müller, Uwe Grether, Pal Pacher* and Jürg Gertsch*, ","doi":"10.1021/acsptsci.4c0026910.1021/acsptsci.4c00269","DOIUrl":"https://doi.org/10.1021/acsptsci.4c00269https://doi.org/10.1021/acsptsci.4c00269","url":null,"abstract":"The cannabinoid CB2 receptor (CB2R) is a potential therapeutic target for distinct forms of tissue injury and inflammatory diseases. To thoroughly investigate the role of CB2R in pathophysiological conditions and for target validation in vivo, optimal pharmacological tool compounds are essential. Despite the sizable progress in the generation of potent and selective CB2R ligands, pharmacokinetic parameters are often neglected for in vivo studies. Here, we report the generation and characterization of a tetra-substituted pyrazole CB2R full agonist named RNB-61 with high potency (Ki 0.13–1.81 nM, depending on species) and a peripherally restricted action due to P-glycoprotein-mediated efflux from the brain. 3H and 14C labeled RNB-61 showed apparent Kd values of <4 nM toward human CB2R in both cell and tissue experiments. The 6,800-fold selectivity over CB1 receptors and negligible off-targets in vitro, combined with high oral bioavailability and suitable systemic pharmacokinetic (PK) properties, prompted the assessment of RNB-61 in a mouse ischemia-reperfusion model of acute kidney injury (AKI) and in a rat model of chronic kidney injury/inflammation and fibrosis (CKI) induced by unilateral ureteral obstruction. RNB-61 exerted dose-dependent nephroprotective and/or antifibrotic effects in the AKI/CKI models. Thus, RNB-61 is an optimal CB2R tool compound for preclinical in vivo studies with superior biophysical and PK properties over generally used CB2R ligands.","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"7 8","pages":"2424–2438 2424–2438"},"PeriodicalIF":4.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsptsci.4c00269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141956727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0